# Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

> **NCT03959540** · — · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 39 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Opicapone
- **DRUG:** Levodopa (L-DOPA) + Standard care

## Key facts

- **NCT ID:** NCT03959540
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-28
- **Primary completion:** 2021-05-11
- **Final completion:** 2021-05-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959540, "Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03959540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*